Meeting
2018 ASCO Annual Meeting
Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
Authors
Jean-Pascal H. Machiels
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Jean-Pascal H. Machiels , Lisa F. Licitra , Yungan Tao , Chia-Jui Yen , Danny Rischin , John Waldron , Barbara Burtness , Vincent Gregoire , Sanjiv S. Agarwala , Jeffrey Yorio , Jean-Pierre Delord , Sercan Aksoy , Sadakatsu Ikeda , Ruey-Long Hong , Joy Yang Ge , Holly M. Brown , Behzad Bidadi , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03040999
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS6094)
DOI
10.1200/JCO.2018.36.15_suppl.TPS6094
Abstract #
TPS6094
Poster Bd #
80a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2017 ASCO Annual Meeting
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
First Author: Jean-Pascal H. Machiels
Poster
2016 ASCO Annual Meeting
Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
First Author: Steven Francis Powell
First Author: Igor Tsaur